264 related articles for article (PubMed ID: 11034738)
1. Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Fish RG; Mason M
Cochrane Database Syst Rev; 2000; 2000(4):CD001986. PubMed ID: 11034738
[TBL] [Abstract][Full Text] [Related]
2. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.
Shelley MD; Kynaston H; Court J; Wilt TJ; Coles B; Burgon K; Mason MD
BJU Int; 2001 Aug; 88(3):209-16. PubMed ID: 11488731
[TBL] [Abstract][Full Text] [Related]
4. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
[TBL] [Abstract][Full Text] [Related]
6. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
8. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
Shelley MD; Wilt TJ; Court J; Coles B; Kynaston H; Mason MD
BJU Int; 2004 Mar; 93(4):485-90. PubMed ID: 15008714
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
[TBL] [Abstract][Full Text] [Related]
10. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer.
Iida K; Naiki T; Kawai N; Etani T; Ando R; Ikegami Y; Okamura T; Kubota H; Okada A; Kohri K; Yasui T
BMC Urol; 2016 Feb; 16():8. PubMed ID: 26920373
[TBL] [Abstract][Full Text] [Related]
12. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
13. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
[TBL] [Abstract][Full Text] [Related]
14. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
15. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer.
Schmidt S; Kunath F; Coles B; Draeger DL; Krabbe LM; Dersch R; Kilian S; Jensen K; Dahm P; Meerpohl JJ
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011935. PubMed ID: 31912907
[TBL] [Abstract][Full Text] [Related]
17. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up.
Shinka T; Matsumoto M; Ogura H; Hirano A; Ohkawa T
Int J Urol; 1997 Mar; 4(2):139-43. PubMed ID: 9179686
[TBL] [Abstract][Full Text] [Related]
19. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
Han RF; Pan JG
Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
[TBL] [Abstract][Full Text] [Related]
20. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
